undamentalytics Newsletter
Sign in

Arcadia Biosciences, Inc. (RKDA) stock

Add to watchlist

Add holding +

NASDAQ: RKDA Nasdaq Agricultural Products & Services Next results ~November 6, 2026

D Fundamentals grade

Arcadia Biosciences, Inc. is a US-listed company in the agricultural products & services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$0.3

Book value (net assets)

Base case. Range ~$0.3–$0.3. Net assets per share: the value if returns just equal the cost of equity.

Price vs value

No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.

Arcadia Biosciences, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds8 adding, 9 cuttingOf 2 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Arcadia Biosciences files

Where Arcadia Biosciences stands after its latest 10-Q

Arcadia Biosciences has little or no product revenue yet; it used $2m of cash in the twelve months to June 2026. That puts it 14 of 16 for growth among the agricultural products & services companies we cover. The diluted share count is up 43.1% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades E. It passes 2 of our 2 financial-health checks. Our book value value is $0.21 a share.

Source: 10-Q filed August 13, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 6, 2026 (estimated)

Arcadia Biosciences, Inc.'s trailing-twelve-month revenue fell 12.2% year on year, with a free-cash-flow margin of -52.6%. Where it lags: net margin of -234.5% ranks 18 of 20 agricultural products & services companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 67.1% while net income fell 47.7%: a 115pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Results due soon. Results are expected around 6 November; the share price can move sharply on the day.
  • Revenue shrinking. Revenue fell 12.2% over the last 12 months.
  • Loss-making. Operating margin is -80.1%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 6.0 points on a year ago.
  • Burning cash. Free cash flow was -52.6% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 43.1% in a year.

Latest results: FY2026 Q2

Filed August 13, 2026
Earnings per share
$0.62 against an average estimate of -$0.54: beat by 214.8%
Revenue
$1m, down 0.8% on a year earlier
Share reaction
-10.7% in the first session after the results on August 13, 2026, against +0.5% for the S&P 500

Arcadia Biosciences' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-1.3%
  • 1 week+2.6%
  • 1 month-45.8%
  • This year-92.1%
  • 1 year-95.8%
  • 5 years-99.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$4.7M
Operating margin
-80.1%
Net margin
-234.5%
EPS (TTM, diluted)
$-5.70

Growth

Revenue growth
−12.2%
Change in growth rate
−2.7 pts
Share count change
+43.1%

Cash

Free cash flow (TTM)
-$2.5M
FCF margin
-52.6%
Stock pay % of revenue
2.1%

Earnings

Last results
August 13, 2026
Next results (est.)
November 6, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Arcadia Biosciences, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 1 valuation models apply; a rating needs 3.

Valuation models

We value Arcadia Biosciences, Inc. as an oil and gas producer, with every model that fits that kind of business. Cost of equity 9.8%: the 10-year Treasury yield (4.9%) plus a beta of 1.07 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Proved-reserve net asset value The SEC standardised measure of the company's proved oil and gas reserves (future net cash flows after tax at SEC average prices, discounted at 10%) less debt and other claims, per share. — Does not apply: no standardised measure of proved reserves in the company's tagged filings
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Book value (net assets) Net assets per share: the value if returns just equal the cost of equity. ~$0.3 Primary model, counts double
Combined value Weighted average of the models that apply: the primary model (book value (net assets)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$0.3 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Arcadia Biosciences, Inc. with oil and gas producers in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$2432.00$736.00$220.00$126.80$219.20$101.20$41.60$10.84$3.13$5.92$1.98$0.16
Market value$173.6bn$81.6bn$24m$24m$70m$50m$44m$13m$4m$8m$3m$304763
+ Net debt (− = net cash)$957000$23m−$9m−$12m−$8m−$11m−$29m−$21m−$7m−$4m−$259000−$4m
Enterprise value$173.6bn$81.7bn$15m$12m$61m$40m$16m−$8m−$3m$4m$2m−$4m
Multiples
Price / sales n/mn/m5.9x16.3x59.7x6.3x6.5x1.8x0.9x1.6x0.6x0.1x
Price / earnings ————————————
Price / free cash flow ————————————
EV / EBITDA ————————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

14 /100

Weak moat

How hard Arcadia Biosciences's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -57.4% of total assets over 10 years.

  • Pricing power 4 / 20

    Gross margin has been a median 34.6%, moving by 22.0 percentage points (standard deviation) across 5 years.

  • Durability 10 / 20

    Operating margin has been a median -277.2%; its worst year was -1634.3%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 10 years, at a median -290.3% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 1511.0% over five years; stock-based pay has been a median 16.8% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Arcadia Biosciences, Inc.: too few analysts cover it.

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2025 −$0.54 $0.62 +214.8%
Jun 2025 −$0.79 −$3.26 −312.7%
Mar 2025 −$0.98 $1.90 +293.9%
Dec 2024 −$0.89 −$2.99 −236.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Positioning

Short interest
14.2%
of tradable shares
Days to cover
0.07
at average volume
Short interest, 1 month
+3469%
to October 15, 2026
Held by institutions
19%
of shares
Held by insiders
15.9%
of shares
Employees
8
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −95.8%

$3.73 on October 31, 2025 to $0.16

ThenNowEffect
Revenue (last 12 months) $5m $5m −12.2%
P/S multiple 0.9x 0.1x −93.2%
Share count 1m 2m −30.1%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
RKDA−59%−74%−71%+89%−67%−92%
Industry peers (median)+4%−25%−15%−1%+3%−4%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
RKDA42%33%25%50%25%9%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
RKDA−82%−90%−82%−48%−71%−95%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 3, 2015: 100% from November 20, 2015 to October 19, 2026. Getting back needed a 2427486% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.14 – $3.90
From 52-week high
−96.0%
vs 50-day average
−53.1%
vs 200-day average
−84.4%
Volatility (1 year)
93%
Beta vs S&P 500
0.83

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
2 up, 10 down
typical move ±7.6%
After a week
1 up, 11 down
typical move ±17.7%
After a month
3 up, 9 down
typical move ±22.4%
Results releasedNext dayS&P 500 next day5 days21 days
August 13, 2026 −10.7% +0.5% −34.0% −35.9%
May 14, 2026 −9.8% −0.4% −14.5% −13.4%
March 26, 2026 −13.5% −3.5% −20.4% −36.4%
November 7, 2025 −7.4% +1.7% −3.3% −2.3%
August 14, 2025 +0.4% −0.2% −6.0% −25.3%
May 8, 2025 −9.8% +0.6% −10.0% +16.3%
March 20, 2025 −8.3% −0.3% −1.2% −16.2%
November 12, 2024 −1.2% −0.3% −33.0% +48.6%
August 13, 2024 −8.9% +2.0% −8.9% −4.8%
May 9, 2024 +4.0% +0.7% +65.2% +43.9%
March 28, 2024 −10.9% −0.2% −6.5% −11.2%
November 9, 2023 −6.3% +0.8% −9.5% −14.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Arcadia Biosciences, Inc. in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Arcadia Biosciences, Inc.
$4M $4.5M $5M $5.5M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $4.6M Revenue (TTM), FY23 Q4: $4.6M Revenue (TTM), FY24 Q1: $4.4M Revenue (TTM), FY24 Q2: $4.4M Revenue (TTM), FY24 Q3: $4.6M Revenue (TTM), FY24 Q4: $5M Revenue (TTM), FY25 Q1: $5.3M Revenue (TTM), FY25 Q2: $5.4M Revenue (TTM), FY25 Q3: $5.2M Revenue (TTM), FY25 Q4: $4.9M Revenue (TTM), FY26 Q1: $4.8M Revenue (TTM), FY26 Q2: $4.7M $4.7M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $4.6M
FY23 Q4 $4.6M
FY24 Q1 $4.4M
FY24 Q2 $4.4M
FY24 Q3 $4.6M
FY24 Q4 $5M
FY25 Q1 $5.3M
FY25 Q2 $5.4M
FY25 Q3 $5.2M
FY25 Q4 $4.9M
FY26 Q1 $4.8M
FY26 Q2 $4.7M
Revenue growth, TTM YoY Arcadia Biosciences, Inc.
-100% -50% 0% 50% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -57.8% Revenue growth, TTM YoY, FY23 Q4: -51.0% Revenue growth, TTM YoY, FY24 Q1: -41.1% Revenue growth, TTM YoY, FY24 Q2: -9.8% Revenue growth, TTM YoY, FY24 Q3: 0.8% Revenue growth, TTM YoY, FY24 Q4: 9.6% Revenue growth, TTM YoY, FY25 Q1: 20.6% Revenue growth, TTM YoY, FY25 Q2: 23.8% Revenue growth, TTM YoY, FY25 Q3: 12.3% Revenue growth, TTM YoY, FY25 Q4: -3.7% Revenue growth, TTM YoY, FY26 Q1: -9.5% Revenue growth, TTM YoY, FY26 Q2: -12.2% -12.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -57.8%
FY23 Q4 -51.0%
FY24 Q1 -41.1%
FY24 Q2 -9.8%
FY24 Q3 0.8%
FY24 Q4 9.6%
FY25 Q1 20.6%
FY25 Q2 23.8%
FY25 Q3 12.3%
FY25 Q4 -3.7%
FY26 Q1 -9.5%
FY26 Q2 -12.2%
Operating margin (TTM) Arcadia Biosciences, Inc.
-300% -200% -100% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -248.9% Operating margin (TTM), FY23 Q4: -171.8% Operating margin (TTM), FY24 Q1: -129.2% Operating margin (TTM), FY24 Q2: -50.3% Operating margin (TTM), FY24 Q3: -55.6% Operating margin (TTM), FY24 Q4: -72.3% Operating margin (TTM), FY25 Q1: -29.1% Operating margin (TTM), FY25 Q2: -74.1% Operating margin (TTM), FY25 Q3: -65.8% Operating margin (TTM), FY25 Q4: -51.4% Operating margin (TTM), FY26 Q1: -80.0% Operating margin (TTM), FY26 Q2: -80.1% -80.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -248.9%
FY23 Q4 -171.8%
FY24 Q1 -129.2%
FY24 Q2 -50.3%
FY24 Q3 -55.6%
FY24 Q4 -72.3%
FY25 Q1 -29.1%
FY25 Q2 -74.1%
FY25 Q3 -65.8%
FY25 Q4 -51.4%
FY26 Q1 -80.0%
FY26 Q2 -80.1%
FCF margin (TTM) Arcadia Biosciences, Inc.
-400% -300% -200% -100% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -296.1% FCF margin (TTM), FY23 Q4: -332.3% FCF margin (TTM), FY24 Q1: -345.4% FCF margin (TTM), FY24 Q2: -291.0% FCF margin (TTM), FY24 Q3: -251.3% FCF margin (TTM), FY24 Q4: -191.1% FCF margin (TTM), FY25 Q1: -152.3% FCF margin (TTM), FY25 Q2: -140.2% FCF margin (TTM), FY25 Q3: -117.7% FCF margin (TTM), FY25 Q4: -96.7% FCF margin (TTM), FY26 Q1: -88.5% FCF margin (TTM), FY26 Q2: -52.6% -52.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -296.1%
FY23 Q4 -332.3%
FY24 Q1 -345.4%
FY24 Q2 -291.0%
FY24 Q3 -251.3%
FY24 Q4 -191.1%
FY25 Q1 -152.3%
FY25 Q2 -140.2%
FY25 Q3 -117.7%
FY25 Q4 -96.7%
FY26 Q1 -88.5%
FY26 Q2 -52.6%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 7 5 3 4 1 1 8 7 7 4 5 5 5
Gross profit — — — — — — 3 −2 1 2 2 2 2
EBITDA −15 −15 −18 −14 −17 −19 −12 −35 −14 −6 −4 −2 −4
Operating income −15 −16 −19 −14 −17 −19 −13 −36 −14 −6 −4 −3 −4
Net income −18 −18 −20 −16 −13 −29 −5 −15 −15 −14 −7 −2 −11
Diluted EPS −$4284.00 −$292.00 −$177.00 −$145.60 −$71.60 −$90.60 −$9.40 −$13.78 −$12.82 −$11.29 −$5.17 −$1.71 −$5.70
Growth (year on year)
Revenue — −22.5% −41.1% +26.3% −63.6% −20.2% +587.3% −15.6% +9.4% −40.0% +13.3% −3.7% −12.2%
Margins
Gross margin — — — — — — 35.3% −28.4% 17.8% 51.2% 41.3% 36.2% 34.6%
EBITDA margin −211.9% −282.0% −574.5% −348.6% <−999% <−999% −151.2% −510.3% −182.9% −134.5% −71.2% −50.8% −79.9%
Operating margin −217.0% −287.5% −584.1% −355.6% <−999% <−999% −159.0% −524.0% −188.8% −137.0% −72.3% −51.5% −80.1%
Net margin −262.7% −331.7% −615.6% −390.1% −920.8% <−999% −57.9% −216.2% −207.3% −313.9% −139.5% −48.1% −234.5%
Free-cash-flow margin −213.9% −281.9% −542.2% −348.8% −948.2% <−999% −405.2% −396.4% −189.4% −343.5% −191.1% −96.7% −52.6%
Cash flow
Cash from operations −15 −15 −17 −14 −14 −17 −30 −26 −14 −15 −10 −5 −2
Capital spending 0 0 0 0 0 1 2 1 0 0 0 0 0
Free cash flow −15 −15 −17 −14 −14 −19 −33 −27 −14 −15 −10 −5 −2
Stock-based pay 1 1 1 1 2 2 2 2 1 1 1 0 0
Free cash flow after stock pay −16 −17 −18 −16 −15 −21 −35 −28 −15 −16 −10 −5 −3
Balance sheet
Cash 17 24 2 9 12 8 14 29 21 7 4 0 4
Total debt 14 25 25 0 0 0 3 0 0 0 0 0 0
Net debt (negative = net cash) −2 1 23 −9 −12 −8 −11 −29 −21 −7 −4 −0 −4
Diluted shares — 71m 111m — — — — 1m 1m 1m 1m 1m 2m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $6m
Short-term assets $6mLonger-term assets $0m
What it owes, and who funded it · $6m
Short-term liabilities $2mLonger-term liabilities $4mShareholders' equity $1m
  • Short-term assets cover short-term liabilities $6m of assets due within a year against $2m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $6m short-term assets against $4m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Arcadia Biosciences, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+43.1%
year over year
R&D spending
0.2%
of revenue
Sales & admin spending
114.7%
of revenue

Competitors: side by side with peers

Closest by revenue in agricultural products & services
Last 12 months unless stated RKDA CBUS PFAI WFCF FAMI ICCC Median
Revenue, last 12 months $5m $4m $3m $25m $28m $31m $149m
Revenue growth, last 12 months −12.2% −10.3% 3.7% −2.2% −56.4% 8.5% −1.1%
Revenue growth, 3-year average −0.7% 137.9% — 0.4% — 25.1% −0.1%
Revenue growth, latest quarter −0.8% 6.5% — 0.7% — 11.5% 6.8%
Gross margin 34.6% 100.0% 38.3% 38.3% 2.9% 40.3% 17.6%
Operating margin −80.1% <−999% −56.3% 5.9% −200.6% 12.6% −5.9%
Operating margin, 3-year average −68.2% <−999% — 8.2% −60.1% 2.1% 2.8%
Net margin −234.5% <−999% −55.8% 5.8% −189.8% 2.6% −0.2%
Cash from operations / revenue −52.6% <−999% −105.1% 5.0% 187.6% 19.2% 3.2%
Free-cash-flow margin −52.6% <−999% −155.6% 4.0% 187.5% 13.7% 2.3%
Free-cash-flow margin, 3-year average −161.3% <−999% — 8.8% 20.0% 5.3% 3.0%
Stock pay / revenue 2.1% 155.6% 1.3% 0.2% 0.0% 1.8% 0.7%
Change in share count 43.1% 95.8% — −3.4% 210.8% 3.4% 2.3%

Median of all 20 companies we cover in agricultural products & services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

20 agricultural products & services companies
Measure Company Peer median Rank
Revenue growth Growth -12.2% -0.8% 17 of 20
Change in growth rate Growth -2.7pp -0.5pp 13 of 20
Gross margin Profitability 34.6% 11.4% 5 of 19
Operating margin Profitability -80.1% -5.9% 13 of 17
Net margin Profitability -234.5% 0.1% 18 of 20
Free-cash-flow margin Cash generation -52.6% 2.5% 17 of 20
Stock pay as % of revenue Cash generation 2.1% 0.8% 14 of 17
Change in share count Balance sheet 43.1% 2.4% 13 of 17

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $4.9M 100.0% ▼ 3.1%
Licenses $0 0.0% ▼ 100.0%
Royalty $0 0.0% ▼ 100.0%
Geography
Region Revenue Share YoY
United States $4.9M 100.0% ▼ 0.9%
AR $0 0.0% ▼ 100.0%
India $0 0.0% ▼ 100.0%
Canada $0 0.0% ▼ 100.0%

From Arcadia Biosciences, Inc.'s 10-K filed March 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$145,768
Institutions reporting
16
Shares held vs prior quarter
▼ 39.5%
Positions opened / closed
8 / 7

Top buyers and sellers, Q2 2026: 8 institutions bought and 9 sold ; the biggest buyer was HRT Financial LP (+88K shares) and the biggest seller Armistice Capital, LLC (−159K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
HRT Financial LP $60,000 88K 41.2% New
Citadel Advisors LLC $16,120 24K 11.1% New
Virtu Financial LLC $15,000 22K 10.3% New
Stonex Group Inc. $11,259 14K 7.7% New
Geode Capital Management, LLC $10,957 16K 7.5% ▼ 49.2%
Xtx Topco Ltd $10,509 15K 7.2% New
State Street Corp $8,248 12K 5.7% 0.0%
Jane Street Group, LLC $6,957 10K 4.8% New
Vanguard Capital Management LLC $6,548 10K 4.5% 0.0%
Sbi Securities Co., Ltd. $81 0K 0.1% 0.0%
TD Waterhouse Canada Inc. $50 0K 0.0% New
UBS Group AG $24 0K 0.0% ▼ 95.7%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Arcadia Biosciences, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 6, 2026 estimated from the company's past filing pattern, not announced

  • August 13, 2026
  • May 14, 2026
  • March 26, 2026
  • November 7, 2025
  • August 14, 2025
  • May 8, 2025

Recent SEC filings

Data status

When each part of this page on Arcadia Biosciences, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Arcadia Biosciences, Inc. in brief

What does Arcadia Biosciences, Inc. do?
Arcadia Biosciences, Inc. is a US-listed company in the agricultural products & services industry. Its financial year ends in December.
What is Arcadia Biosciences, Inc.'s stock ticker?
Arcadia Biosciences, Inc. trades under the ticker RKDA on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Arcadia Biosciences, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Arcadia Biosciences, Inc. reported revenue of $4.7M, 12.2% lower than a year earlier, according to its SEC filings.
What is Arcadia Biosciences, Inc.'s free cash flow?
Arcadia Biosciences, Inc.'s free-cash-flow margin is -52.6% of revenue over the trailing twelve months, ranking 17 of the 20 agricultural products & services companies we cover.
Who are Arcadia Biosciences, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are HRT Financial LP, Citadel Advisors LLC and Virtu Financial LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Arcadia Biosciences, Inc.'s market cap?
On November 2, 2026, Arcadia Biosciences, Inc.'s market capitalisation was about $304,763 and net debt of -$4.2M. Market figures come from third-party market data and may be delayed.
Who are Arcadia Biosciences, Inc.'s competitors?
In our Agricultural Products & Services peer group, the companies closest to Arcadia Biosciences, Inc. are Cibus, Inc., Pinnacle Food Group Ltd, Where Food Comes From, Inc., Farmmi, Inc. and Immucell Corp. The side-by-side comparison below sets their revenue, margins and growth against Arcadia Biosciences, Inc.'s.
When is Arcadia Biosciences, Inc.'s next earnings date?
Around November 6, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Arcadia Biosciences, Inc. announces its own schedule.